Modena, cardiology scandal. The reasons for the sentence: "Sangiorgi enslaved to companies"

The judges: "The foundations of illicit agreements for money, contacts and prestige were laid for scientific purposes"

CARDIOLOGY CASE

MODENA. «Il Tribunale ha avuto la netta percezione che il fine abbia giustificato i mezzi per cui, se le cose erano fatte a fin di bene (le sperimentazioni fatte per migliorare la pratica clinica, l’efficacia di un farmaco o la funzionalità di un dispositivo medico, in definitiva per migliorare la salute dei pazienti) e ciò avveniva anche con vantaggio dell’ospedale e della casa farmaceutica, pur senza falsare o modificare i dati, allora si poteva fare tutto. In realtà, è su questo malcelato scenario di finalità di alto profilo scientifico ma prima ancora etico che si gettano le basi per ottenere ciò che si vuole a tutti i costi, con i tempi scanditi da altri soggetti – le case farmaceutiche – che non dovrebbero ingerirsi nella sperimentazione, e con l’omessa indicazione delle cointeressenze presenti all’inizio di uno studio».

A UNIQUE CASE. This is one of the crucial passages of the 660-page sentence filed by the Court, presided over by judge Barbara Malvasi, which motivates the total 36-year sentences of cardiologists and managers of biomedical companies at the end of the epochal trial on Cardiology of the Polyclinic since 2009 to 2012 and above all on the figure of Professor Massimo Sangiorgi, director of Hemodynamics believed to be the director of the criminal association for corruption and aggravated fraud, especially to the detriment of the Polyclinic and the Region. An impressive investigation and, as the judges explained at the beginning of the sentence, of great interest due to the uniqueness of the subject and the ability to penetrate a complex world such as that of experimental cardiology, the center of profound technological innovations and therefore of medical experimentation. Experiments such as those which, according to the court, were also conducted in an abusive way and for profit reasons through underground agreements between Sangiorgi, his staff and the biomedical companies that sponsored him through some non-profit organizations created for this purpose.

LAWFUL AND ILLEGAL. What is the boundary between the lawful and the unlawful? The question has covered all the hearings of this mammoth trial for a city like Modena. The judges' answer concerns, on the one hand, the difference between "profit" trials (therefore sponsored or to obtain profits) and "non-profit" trials (dedicated to patients). Then there is a second watershed, they write: «The regulation of the Polyclinic provides that the fees for the investigators are paid only by the hospital, deducting them from the sums received under the contracts stipulated with the sponsor companies, while direct contacts are not envisaged between companies and ricercatori. È di tutta evidenza il carattere indebito di quanto percepito: si privatizza un rapporto con gli sponsor degli studi clinici che è regolato da norme pubblicistiche e si determina l’ingiusta sottrazione alla azienda ospedaliera di somme che per legge le spettano (ciò che sarà rilevante per la configurazione dei reati di truffa di volta in volta contestati)».

HIDDEN AND SHUT UP. Sangiorgi and his collaborators were also aware of this difference, according to the judges in a proven way (the positions, here impossible to summarize, are different according to the evidence): on the one hand agreements and experiments were concealed and on the else the law of silence was in force, an instrument of fraud. Underground payments were made to the non-profit organizations created on purpose. The judges write: «The two violations that the Court considered decisive for determining the abusive nature of the experimentation are those relating to the creation of a non-profit organization as a shell entity which fictitiously interposed between the pharmaceutical company and Sangiorgi and the conflict of interest from time to time once detected in relation to the concomitant collaboration or consultancy relationships - not declared - by the investigator: therefore, due to the methods with which the study was carried out, the independence of the doctor was incontrovertibly compromised".

LABOR TAXES". The long list of cash "contributions" is reported in detail but in several points, case by case, the judges admit that it is impossible to arrive at quantifying definitive damage to the Polyclinic, even if it is certainly large sums. In short, there is no longer talk of sums donated for experimentation, but of the corruption of doctors as public officials regulated by precise rules and laws. Like the internal rules that the Polyclinic made explicit in the documents to be signed and Sangiorgi said he did not know. Sangiorgi's ignorance which according to the judges is denied by 12 requests for external collaboration. It is at this point that the scam enters: «The corollary of corruption is the scam: the elements of artifice configured in Sangiorgi's repeated false declarations build a different appearance of reality, regarding the "profit" nature of the experimentation, from which they error of the Policlinico a series of prejudicial patrimonial deeds ».

SUBJECT TO COMPANIES. The corruptive pact then has its obvious nature: "The debasement of the public health function has resulted in its enslavement to the commercial logic of the pharmaceutical companies". “However, it's not just about money and publications. A multiplier effect of the opportunities for corruption has been created since through the management of the experimentation package at the Polyclinic, Sangiorgi has been perfectly capable of maintaining a series of close relationships with important pharmaceutical companies, through which all sorts of opportunities are generated both scientific notoriety also at an international level to increase his reputation as a distinguished clinician and scientist, as well as connections and business relationships with companies which often translate into well-paid consultancy assignments». Looking at the story from above, the judges point out a serious lack of organizational models at every level which has made it possible to create this "infamous pact" between biomedical companies and the hospital's internal investigator.

 

Editor's note: Le “case farmaceutiche” così definite nell’articolo sono aziende di dispositivi

Exit mobile version